{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-067071","form_type":"8-K","ticker":null,"cik":"0001641640","company_name":"Nabriva Therapeutics plc","filed_at":"2023-06-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.795174+00:00","generated_at":"2026-06-14T09:25:42.407844+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Nabriva receives Nasdaq delisting notice over negative equity of -$4.4M","bullets":["Stockholders' equity of -$4,357,000 as of March 31, 2023, below $2.5M minimum.","Nasdaq letter received May 25, 2023; company has until July 10, 2023 to submit compliance plan.","If plan accepted, extension of up to 180 days from May 25 may be granted.","Alternative listing standards (market value or net income) not currently met.","No immediate impact on listing but delisting risk if compliance not regained."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-067071","json":"https://secwatch.observer/filing/0001104659-23-067071.json","markdown":"https://secwatch.observer/filing/0001104659-23-067071.md","text":"https://secwatch.observer/filing/0001104659-23-067071.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1641640/000110465923067071/0001104659-23-067071-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1641640/000110465923067071/tm2317450d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T09:25:42.407844+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3da006e9af0bb5a4ebde3b0b563c66810ee15d54","claim":"Nabriva Therapeutics plc received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).","evidence_excerpt":"May 25, 2023, Nabriva Therapeutics plc (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company was not in compliance with Nasdaq Listing Rule 5550(b)(1) (the “Rule”) because the stockholders’ equity (deficit) of the Company of $(4,357,000) as of March 31, 2023, as reported in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023, was below the minimum stockholders’ equity requirement of $2,500,000. As of the date of this Current Report on Form 8-K, the Company does not meet the alternative standards for continui","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1641640/000110465923067071/0001104659-23-067071-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"stockholders equity"},{"label":"Rules","value":"5550(b)(1)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}